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Abstract
Since the identification of MECP2 as the causative gene in the majority of Rett Syndrome (RTT) cases, transgenic mouse
models have played a critical role in our understanding of this disease. The use of additional mammalian RTT models offers
the promise of further elucidating critical early mechanisms of disease as well as providing new avenues for translational
studies. We have identified significant abnormalities in growth as well as motor and behavioural function in a novel zinc-
finger nuclease model of RTT utilizing both male and female rats throughout development. Male rats lacking MeCP2
(Mecp2ZFN/y) were noticeably symptomatic as early as postnatal day 21, with most dying by postnatal day 55, while females
lacking one copy of Mecp2 (Mecp2ZFN/þ) displayed a more protracted disease course. Brain weights of Mecp2ZFN/y and Mecp2ZFN/
þrats were significantly reduced by postnatal day 14 and 21, respectively. Early motor and breathing abnormalities were ap-
parent in Mecp2ZFN/y rats, whereas Mecp2ZFN/þrats displayed functional irregularities later in development. The large size of
this species will provide profound advantages in the identification of early disease mechanisms and the development of ap-
propriately timed therapeutics. The current study establishes a foundational basis for the continued utilization of this rat
model in future RTT research.
Introduction
Rett Syndrome (RTT) is an X-linked neurodevelopmental disor-
der affecting approximately 1 in 10 000 girls annually (1) that is
caused by mutations in the gene encoding the transcriptional
regulator MeCP2 in over 95% of typical cases (2–5). The syn-
drome is marked by seemingly normal development until 6–18
months of age, at which point language, motor, social and cog-
nitive skills regress, cephalic growth decelerates, and hand ster-
eotypies and breathing abnormalities appear (5–8). Although
emerging longitudinal data suggest that females with RTT may
live well into their fifties (9), the disease nonetheless has devas-
tating impacts on quality of life.
Historically, RTT has been studied primarily through the use
of genetically manipulated mouse models with alterations in
the Mecp2 gene (10–22), all of which display a range of abnormal
neurologic phenotypes. Overall, these models have been rela-
tively successful in recapitulating many of the features ob-
served in the clinical progression of RTT (for an extensive
review of existing RTT mouse models, see references (23–26).
Although many studies thoroughly examined phenotypes in
overtly “symptomatic” male and less frequently female
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animals, few have fully characterized these models beginning
early in development. Given that RTT is a pervasive develop-
mental disorder presenting with an initial period of “normality”
followed by severe regression and subsequent pseudostationary
and deterioration phases, it is important to remain cognizant of
the pathophysiologic changes that may occur in any model
throughout each stage of development. This is especially critical
when considering the potential for a targeted therapeutic win-
dow early in disease progression.
Although mice have long been the preferred species in the
modelling of genetic disorders, relatively recent advances in the
ability to manipulate the rat genome offer unique opportunities,
especially in the study of central nervous system (CNS) diseases
like RTT. Relative to the mouse, the increased size of the rat,
and subsequently all of its anatomical structures, offers obvious
advantages in a surgical setting, but confers additional benefits
when considering the importance of structure size and spatial
relationship in both region-specific and age-dependent studies
of the CNS. Electrophysiological studies and direct drug delivery
experiments, for example, are considerably easier when dealing
with large rat structures, an effect that is magnified if studies
are performed at very early developmental stages. It is also well
established that, compared to mice, rats demonstrate a wider
variety of more complex cognitive and social behaviours for
which testing paradigms are available and validated (27–35). All
of these factors make the use of a rat model an appropriate
choice for the study of a neurodevelopmental disorder such as
RTT, in which deficits of higher cognitive functioning and social
interaction predominate, and examination at early develop-
mental time points may be critically relevant to therapeutic po-
tential. Aside from these specific advantages, the addition of a
rat model to the collection of resources currently available in
the study of RTT will provide a platform for validating and com-
paring behavioural phenotypes in different species with differ-
ent genetic backgrounds, thus making possible a more
complete understanding of complex disease mechanisms
which will facilitate translatable pharmaceutical development.
With these considerations in mind, we sought to establish
the utility of a novel zinc-finger nuclease rat model of RTT, gen-
erated by Sage laboratories, by characterizing its motor and
behavioural phenotypes that recapitulate the fundamental fea-
tures observed in existing RTT mouse models as well as human
RTT patients. This model contains a 71 base pair deletion in
exon 4 of the Mecp2 gene, resulting in the absence of MeCP2 pro-
tein. As one of the first characterizations of the motor and
behavioural phenotypes in this model, we felt it important to
follow both male and female rats through the entirety of their
development. We herein report that brain weight is reduced in
this RTT rat model by postnatal day (PND) 14, both motor and
behavioural deficits are clearly observed as early as the fourth
postnatal week, and these deficits continue throughout
development.
Results
Mecp2 transcript and protein levels are altered in
Mecp2ZFN/y andMecp2ZFN/þrats
Sprague Dawley females lacking one copy of Mecp2 (Sage labs)
were created using zinc-finger nuclease technology that re-
sulted in a 71 base pair deletion in the 4th exon of the Mecp2
gene. Breeding of these female rats to wildtype (WT) Sprague
Dawley males produced progeny in the expected Mendelian ra-
tios. Genotyping differentiated WT animals from male rats
lacking MeCP2 (Mecp2ZFN/y) and female rats lacking one copy of
Mecp2 (Mecp2ZFN/þ) (Fig. 1A). Utilizing a C-terminus targeted an-
tibody, western blot analysis of tissue isolated from the cortex
and brainstem indicated a complete absence of full length
MeCP2 in Mecp2ZFN/y rats as compared to WT males (Fig. 1B).
Cortical MeCP2 protein expression was significantly reduced by
52% in 15-month-old Mecp2ZFN/þ rats relative to WT females (Fig.
1C–D). In a complementary study by Veeratagaven et al. western
blot analysis utilizing an N-terminus targeted antibody also
confirmed the absence of truncated MeCP2.
Mecp2ZFN/y males andMecp2ZFN/þ rats display altered
brain and body weights early in development
In evaluating the general phenotype of these animals, we
sought to determine if Mecp2ZFN/y or Mecp2ZFN/þ rats displayed
alterations in either body or brain growth, as has been previ-
ously reported in knockout and Mecp2 heterozygous mice (10–
13,16,19–22,36–44). One obstacle in the evaluation of this data
proved to be the development of dental malocclusion (Fig. 2A)
in approximately 80% of Mecp2ZFN/y rats (data not shown) by
PND 50. This was infrequently observed in Mecp2ZFN/þ rats dur-
ing the 18-month period of data collection, and this trait was
never observed in WT animals of either sex (data not shown).
For all studies described herein, animals that demonstrated ac-
tive malocclusion were excluded from further testing. Body
weights of Mecp2ZFN/y rats that did not develop malocclusion by
PND 50 did not differ significantly from WTs at any of the devel-
opmental time points examined (Fig. 2B). Interestingly, many
Mecp2ZFN/y rats that went on to develop malocclusion were gen-
erally smaller than their WT counterparts starting early in de-
velopment, before tooth lengthening. In general, Mecp2ZFN/y rats
displayed a normal habitus but felt, upon handling, hypotonic
and limp when compared to WT littermates (see
Supplementary Material, video 1, where the two less active ani-
mals are Mecp2ZFN/y and the two most active males are wild-
types). Mecp2ZFN/þ rats displayed a tendency for weight gain,
becoming significantly heavier than WTs by PND 60-90 and
maintaining an endomorphic habitus, on average, throughout
development (Fig. 2C and D). Mecp2ZFN/þrats also displayed a
subjectively increased incidence of hypotonia, especially at later
time points. Evaluation of wet brain weights revealed that
Mecp2ZFN/y brains weighed significantly less than their WT litter-
mates as early as PND 14 (Fig. 2E). Similarly, the brains of
Mecp2ZFN/þ rats weighed significantly less than that of WT litter-
mate females beginning at PND 21 (Fig. 2F).
Mecp2ZFN/y andMecp2ZFN/þrats display diminished
overall wellness and decreased survival
A symptom score was generated for the animals used in this
study by weekly monitoring for general wellness, and the pres-
ence and severity or absence of specific characteristics. Possible
symptom scores ranged from 0 to 9 (Table 1), with WTs typically
scoring close to 0. We did not score the presence of tremors,
head nodding, and seizures in male and female animals, al-
though these features were observed on occasion during han-
dling and behavioural testing (see Supplementary Material,
video 2 for Mecp2ZFN/y and Supplementary Material, video 3 for
Mecp2ZFN/þ). Mecp2ZFN/y rats demonstrated symptoms relatively
early in development, with many displaying a “scruffy” fur ap-
pearance and a general lethargy compared to their WT litter-
mates. Infrequently, Mecp2ZFN/y rats displayed malocclusion as
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Figure 1.Mecp2ZFN/y male and Mecp2ZFN/þ female rats display altered MeCP2 protein expression. (A) Representative genotyping gel revealing DNA fragments of different
lengths that differentiate WT from Mecp2ZFN/y and Mecp2ZFN/þ rats. (B) Western blotting demonstrates total absence of MeCP2 protein in both cortex and brainstem of
PND 60–80 Mecp2ZFN/y rats. (C–D) 15-month-old Mecp2ZFN/þ rats show a 52% reduction in MeCP2 protein by western blotting of cortical tissue (WT n¼4 Mecp2ZFN/þ
n¼4). Data are presented as mean6 SE, with asterisks representing significant genotype differences (**P<0.01).
Figure 2. Mecp2ZFN/y and Mecp2ZFN/þ rats display altered body and brain weights throughout development. (A) Representative example of early malocclusion in a PND
28 Mecp2ZFN/y rat. (B) Mecp2ZFN/y body weight does not significantly differ from WT body weight throughout development. (PND 21 WT n¼13 Mecp2ZFN/y n¼ 11; PND
28 WT n¼12 Mecp2ZFN/y n¼10; PND 35 WT n¼7 Mecp2ZFN/y n¼ 8; PND 42 WT n¼7 Mecp2ZFN/y n¼8; PND 50 WT n¼13 Mecp2ZFN/y n¼11; PND 57 WT n¼11 Mecp2ZFN/y
n¼9; PND 64 WT n¼3 Mecp2ZFN/y n¼4) (C–D) Mecp2ZFN/þ females are significantly heavier than WTs beginning at postnatal day 60 and continuing through 18 months
of age (PND 21 WT n¼21 Mecp2ZFN/þ n¼25; PND 60–90 WT n¼23 Mecp2ZFN/þ n¼ 22; 6 mo WT n¼ 21 Mecp2ZFN/þ n¼25; 9 mo WT n¼14 Mecp2ZFN/þ n¼14; 12 mo WT n¼12
Mecp2ZFN/þ n¼ 13; 15 mo WT n¼13 Mecp2ZFN/þ n¼13; 18 mo WT n¼ 5 Mecp2ZFN/þ n¼ 5). (E) Mecp2ZFN/y males display significantly decreased brain weight beginning at
postnatal day 14 and continuing throughout development. (PND 7 WT n¼ 5 Mecp2ZFN/y n¼7; PND 14 WT n¼5 Mecp2ZFN/y n¼6; PND 21 WT n¼6 Mecp2ZFN/y n¼6; PND 28–
35 WT n¼6 Mecp2ZFN/y n¼9; PND 47–55 WT n¼9 Mecp2ZFN/y n¼ 10; PND 60–80 WT n¼6 Mecp2ZFN/y n¼5). (F) Mecp2ZFN/þ females demonstrate significantly decreased
brain weight beginning at postnatal day 21 and continuing through 18 months of age. (PND 7 WT n¼ 4 Mecp2ZFN/þ n¼7; PND 21 WT n¼5 Mecp2ZFN/þ n¼3; PND 60–90 WT
n¼5 Mecp2ZFN/þ n¼7; 15 mo WT n¼5 Mecp2ZFN/þ n¼6; 18 mo WT n¼8 Mecp2ZFN/þ n¼7). Data are presented as mean 6 SE, with asterisks representing significant geno-
type differences (*P<0.05, **P<0.01, ***P< 0.00 1).
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early as PND 21. Mecp2ZFN/y males occasionally exhibited re-
tracted testes as early as PND 21, and the appearance of a shriv-
elled scrotum often continued throughout adulthood (see
Supplementary Material, video 1 for examples of this trait).
Mecp2ZFN/y rats developed symptoms quickly, and deteriorated
rapidly, with symptom scores averaging above 5 by 3 weeks
post-weaning (Fig. 3A). Mecp2ZFN/þ females displayed a more
gradual increase in symptom score from PND 21–28 through 9
months of age, with the average score being between 3 and 4 for
9-month-old Mecp2ZFN/þrats (Fig. 3B). WT male and female
symptom scores above 0 were typically due to a mild develop-
mental decrease in activity level, which is reflected in
Figure 4A–G, or by fur loss around the face and dorsal body,
which followed a pattern of cagemate-initiated barbering that
has previously been reported in rodents (45). Hindlimb clasping
(Fig. 3C), which is considered an identifying characteristic of
symptomatic RTT mice, was observed in approximately 70% of
Mecp2ZFN/y and Mecp2ZFN/þ rats by PND 50 and 9 months of age,
respectively (data not shown). For an example of this feature,
see Supplementary Material, video 4, in which a WT male is pre-
sented first, followed by a Mecp2ZFN/y male demonstrating hin-
dlimb clasping and wide-based gait.
In order to address findings of decreased RTT animal sur-
vival in previous studies (10–13,20,21,37), a Kaplan-Meier
survival curve was constructed from only those Mecp2ZFN/y rats
that died of causes unrelated to nutritional status or littermate
aggression, and compared to WT littermates. This curve dem-
onstrates that approximately half of all Mecp2ZFN/y males died
by PND 55 (Fig. 3D). Of note is the observed incidence of
Mecp2ZFN/y on Mecp2ZFN/y littermate aggression, which ac-
counted for many cases of severe open flank and hindquarter
wounds that resulted in abrupt death or necessitated sacrifice
(data not shown). A Kaplan-Meier curve was not constructed for
Mecp2ZFN/þ rats, as none of these animals died spontaneously of
disease-related causes throughout the period of study; however,
several were sacrificed due to severe obesity leading to an in-
ability to groom, and 2 (> 12 months of age) were sacrificed due
to severely deteriorating body condition.
Mecp2ZFN/y andMecp2ZFN/þrats display altered
locomotion upon open field testing
Due to the general lethargy observed in Mecp2ZFN/y rats begin-
ning at an early age and continuing through development (see
Supplementary Material, videos 1 and 4), and Mecp2ZFN/þ fe-
males at later time points, we sought to evaluate the overall lo-
comotor activity by use of the open field test. We began our
studies using Mecp2
ZFN/y
rats and compared them with WT litter-
mates at PND 21–28 (early symptomatic) and PND 40þ (late
symptomatic) time points. Mecp2ZFN/y males displayed a de-
crease in overall distance travelled, average velocity, and per-
cent of total time spent highly mobile when compared to WT
littermates (Fig. 4A–C). A representative activity tracing from
one trial in late symptomatic animals is shown in Figure 4D. In
contrast to WT animals, which demonstrate substantial explor-
atory behaviour, Mecp2ZFN/y littermates moved little, if at all,
from the location of their placement in the centre of the open
field for the duration of the trial. This limited locomotor pattern
made the evaluation of anxiety phenotype by the measurement
of time spent in the arena centre inappropriately influenced by
motor deficits, and thus unsuitable for analysis. Mecp2ZFN/þ rats
displayed a trend toward a decrease in distance travelled, aver-
age velocity, and time spent highly mobile, with these
parameters showing genotype-specific statistical significance at
only one or two time points between the age of weaning and 15
months (Fig. 4E–G).
Mecp2ZFN/y andMecp2ZFN/þrats display motor
abnormalities throughout development
We frequently observed Mecp2ZFN/y and Mecp2ZFN/þ rats display-
ing a “waddling” gait, where the hindlimbs swung widely about
the base or appeared to partially drag on the floor in their home-
cages or the open field arena surface during testing. We there-
fore next pursued two locomotor tests, rotor rod and CatwalkTM,
to assess motor abnormalities.
Unlike open field testing, which assesses the general activity
level of a freely moving animal, rotor rod tests motor coordina-
tion while providing motivation by exploiting a natural fear of
falling off of the rotating rod. We observed a significant decrease
in latency to fall in Mecp2ZFN/y rats relative to WT littermates at
both early (PND 21–28) and late (PND 40þ) developmental time
points (Fig. 5A). Mecp2ZFN/þ females also demonstrated a de-
creased latency to fall at 9 months of age compared to WT litter-
mate controls (Fig. 5B). Testing of females older than 9 months
of age was not assessed due to the frequency of obesity in the
Mecp2ZFN/þpopulation, which made placement on the rotating
rod not possible.
Given the abnormal gait we observed in male and female an-
imals, we additionally pursued more complex gait analysis via
CatwalkTM software in order to identify potential alterations in
footfall patterns and limb support among Mecp2ZFN/y and
Mecp2ZFN/þpopulations. Where applicable, right-sided motor
traits were evaluated, as no lateralization of deficits was ex-
pected in this disease model. Like rotor rod, CatwalkTM provides
motivation for animal movement, in this case via the
Figure 3.Mecp2ZFN/y and Mecp2ZFN/þ rats display diminished overall wellness and
decreased survival. (A) Mecp2ZFN/y males and (B) Mecp2ZFN/þ females display in-
creased overall symptom scores relative to WTs throughout development
(Males: PND 21–28 WT n¼43 Mecp2ZFN/y n¼46; PND 35–42 WT n¼23 Mecp2ZFN/y
n¼25; PND 49–55 WT n¼ 19 Mecp2ZFN/y n¼17; PND 60þ WT n¼5 Mecp2ZFN/y n¼7;
Females: PND 21–28 WT n¼ 10 Mecp2ZFN/þ n¼16; 6 mo WT n¼ 15 Mecp2ZFN/þ
n¼15; 9 mo WT n¼7 Mecp2ZFN/þ n¼ 12). (C) Representative photograph of hin-
dlimb clasping in an adult Mecp2ZFN/y rat. (D) A Kaplan–Meier survival curve
demonstrates that half of Mecp2ZFN/y males have died by PND 55 (WT n¼11
Mecp2ZFN/y n¼7). Data are presented as mean 6 SE, with asterisks representing
significant differences (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
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Figure 4.Mecp2ZFN/y and Mecp2ZFN/þ rats display altered locomotion upon open field testing. (A–C)Mecp2ZFN/y males demonstrate a significantly decreased distance trav-
elled (A), average velocity (B), and time spent in a highly mobile state (C) when compared to WTs at both early and late developmental time points (PND 21–28 WT
n¼31 Mecp2ZFN/y n¼24; PND 40þ WT n¼21 Mecp2ZFN/y n¼21). (D) Representative tracings of open field movement for PND 40þ WT (left) and Mecp2ZFN/y (right) males.
(E–G) Mecp2ZFN/þ females display a significantly decreased distance travelled (E) and average velocity (F) at 12 months of age when compared to WT females, as well as
(G) decreased time spent in a highly mobile state at 6 and 12 months of age (PND 21–28 WT n¼11 Mecp2ZFN/þ n¼12; PND 40–70 WT n¼10 Mecp2ZFN/þ n¼10; 6 mo WT
n¼11 Mecp2ZFN/þ n¼15; 9 mo WT n¼10 Mecp2ZFN/þ n¼12; 12 mo WT n¼10 Mecp2ZFN/þ n¼10; 15 mo WT n¼10 Mecp2ZFN/þ n¼12). Data are presented as mean 6 SE,
with asterisks representing significant genotype differences (*P< 0.05, **P<0.01, ***P<0.001).
Table 1. Symptom score generation. Table summarizing the score generation paradigm used to calculate a weekly symptom score for every
animal reported
Symptom Score (Total 5 0–9)
0 1 2
Activity level Normal (rearing,
cage exploration,
cagemate interaction)
Lethargic (no rearing,
minimal exploration
and interaction)
Little to no movement
(appears lifeless or asleep)
Hindlimb clasp Absent Present –
Breathing abnormalities Absent Present –
Low-clearance gait/waddle Absent Present –
Dirty/unkempt coat, Piloerection Absent Present –
Urine staining around genitalia Absent Present –
Porphyrin around eyes/nose Absent Present –
Fur loss Absent Present –
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placement of a dark box at one end of a narrow glass plate onto
which the animal is initially placed at the opposite open-ended
side. CatwalkTM testing of Mecp2ZFN/y rats demonstrated a de-
creased crossing speed and an increased number of steps taken
to cross the glass walkway at PND 50 and beyond relative to WT
littermates (Fig. 6A–B). Although a lack of significant change in
crossing speed between younger WT and Mecp2ZFN/y males may
seem contrary to previously mentioned findings of decreased
velocity detected in open field testing at this age, this may be
explained by the added motivational factor present in
CatwalkTM testing but absent in the open field. Mecp2ZFN/y rats
displayed a decreased incidence of gait involving the simulta-
neous contact of 3 paws at both early (PND 21–28) and late (PND
50þ) time points (Fig. 6C). Additionally, right hindlimb swing
speed was decreased in Mecp2ZFN/y rats beginning at PND 21–28,
and both right front and hindlimb swing speed and stride length
were decreased at PND 50 and beyond (Fig. 6D–E). Despite these
observed differences between Mecp2ZFN/y and WT males, there
was no significant genotype-specific alteration in the regularity
index, a measure of the normality of footfall patterns, at either
time point evaluated (Fig. 6F). It is important to consider, how-
ever, that a repeating footfall pattern of any type, even if not
demonstrated in the WT population, contributed to an in-
creased regularity index in Mecp2ZFN/y rats. Thus, Mecp2ZFN/y
males seem to maintain some type of regularity during locomo-
tion, potentially mediated through alterations in support type,
as mentioned above. The significant differences in Mecp2ZFN/y
paw placement are shown in a representative CatwalkTM trac-
ing (Fig. 6G) as well as in Supplementary Material, videos 5
(wildtype) and 6 (Mecp2ZFN/y), where dragging of the abdomen
can also be noted as an indicator of the aforementioned low-
clearance gait.
CatwalkTM testing revealed that Mecp2ZFN/þ rats displayed
significant deviations from WT motor patterns at various time
points, with relatively clear trends toward alterations through-
out development. Mecp2ZFN/þcrossing speed was decreased (Fig.
7A) and number of steps increased at both 6 and 9 months of
age (Fig. 7B). Usage of 3-paw support during movement was de-
creased in Mecp2ZFN/þ rats at one week post-weaning as well as
12 and 15 months of age (Fig. 7C). The base of support, or width
of stance, between hind paws was found to be increased in
Mecp2ZFN/þ rats beginning at 6 months of age and continuing
through 15 months of age (Fig. 7D), although the higher weight
of Mecp2ZFN/þ females may have contributed to leg splay in such
a manner that was not controlled for in these experiments.
However, the base of support of the front paws did not differ
between Mecp2ZFN/þand WTs throughout development, suggest-
ing that the hindpaw stance width increase in Mecp2ZFN/þ rats
may be a true compensatory gait alteration. While right hind
print area was decreased in Mecp2ZFN/þ rats only at PND 21–28
(Fig. 7E), and right front print area did not differ, true relative
print areas are difficult to compare due to the significantly
larger average weights of Mecp2ZFN/þ rats beginning at PND 60–
90 (Fig. 2D), which may have artificially inflated values relative
to WTs. Regularity index did not differ between WTs and
Mecp2ZFN/þ rats at any point throughout development (Fig. 7F);
however, forelimb stride length and swing speed were de-
creased in Mecp2ZFN/þ females relative to WT at 6 and 9 months,
with stride length remaining decreased at 15 months of age (Fig.
7G–H). Identical trends held true for hindlimb stride length and
swing speed (Fig. 7I–J).
Mecp2ZFN/y rats display respiratory abnormalities early
in development
Respiratory activity was measured in juvenile male (PND 21–28),
adult male (PND 40þ), and aged (18 month) female rats by
whole-body plethysmography. We found that under control
conditions (awake and breathing room air) juvenile Mecp2ZFN/y
rats exhibited abnormal breathing compared to WTs
(Supplementary Material, video 7, Fig. 8A–B). Juvenile WTs
breathed at a rate of 126.665.3 BPM, which is comparable to re-
spiratory rates of similarly aged Sprague-Dawley rats (46);
however, age-matched Mecp2ZFN/y rats breathed at a rate of only
100.164.7 BPM (Fig. 8A and C). The reduction in frequency was
due to both an increase in inspiratory time (Ti) (0.206 0.01 s WT
vs. 0.2560.01 s Mecp2ZFN/y) (Fig. 8D) and expiratory time (Te)
(0.286 0.01 sec WT vs. 0.3760.03 s Mecp2ZFN/y) (Fig. 8E). Despite
these changes in respiratory frequency, juvenile Mecp2ZFN/y
males exhibit an otherwise normal tidal volume (45.663.0 ml/
kg WT vs. 53.063.2 ml/kg Mecp2ZFN/y) (Fig. 8F), minute ventila-
tion (57586425.0 ml/min/kg WT vs. 53686505.4 ml/min/kg
Mecp2ZFN/y) (Fig. 8G), a relatively stable respiratory cycle (irregu-
larity score¼ 5.06 0.6 WT vs. 5.160.6 Mecp2ZFN/y) (Fig. 8H), and a
similar number of spontaneous apneas (Fig. 8I), but of a shorter
duration compared to controls (2.56 0.1 s WT; 2.16 0.1 s
Mecp2ZFN/y) (Fig. 8J and B).
Respiratory activity was also measured in adult (PND40þ)
Mecp2ZFN/y males and aged (18 months) Mecp2ZFN/þ females. The
respiratory phenotype of adult (PND40þ) Mecp2ZFN/y rats was
similar to that described above for juvenile animals, i.e.,
Figure 5. Mecp2ZFN/y and Mecp2ZFN/þ rats display deficits upon rotor rod testing. (A) Mecp2ZFN/y males fall from the rotating rod significantly sooner than WTs at both
early and late developmental time points. (PND 21–28 WT n¼17 Mecp2ZFN/y n¼25; PND 40þWT n¼ 16 Mecp2ZFN/y n¼15) (B) 9 month old Mecp2ZFN/þ females display a de-
creased latency to fall when compared to age-matched WTs. (PND 21–28 WT n¼8 Mecp2ZFN/þ n¼8; PND 40–60 WT n¼ 10 Mecp2ZFN/þ n¼10; 9 mo WT¼7 Mecp2ZFN/þ
n¼6) Data are presented as mean 6 SE, with asterisks representing significant genotype differences (**P<0.01).
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hypoventilation (111.962.8 BPM WT vs. 87.76 7.8 BPM
Mecp2ZFN/y) (Fig. 8C) and reduced apnea duration (3.360.2 sec
WT vs. 2.360.1 Mecp2ZFN/y) (Fig. 8J), but with otherwise normal
outcome measures (Fig. 8D–I). Conversely, aged Mecp2ZFN/þ fe-
males show an enhanced respiratory frequency (57.862.7 BPM
WT vs. 82.56 7.2 BPM Mecp2
ZFN/þ
) (Fig. 9A) in conjunction with re-
duced expiratory time (Te) (0.7560.05 sec WT vs. 0.4660.04 sec
Mecp2ZFN/þ) (Fig. 9B). All other outcome measures were normal
in Mecp2ZFN/þ females (Fig. 9C–H).
Regardless of age or gender, apneic events were typically
preceded by a sigh-like augmented breath in both WT and
MeCP2-deficient animals (Fig. 8B); however, unlike WT ani-
mals, Mecp2ZFN/y rats showed little expiratory component asso-
ciated with this augmented breathe, perhaps suggestive of
breath-hold like behaviour. It is worth noting anecdotally that
juvenile and adult WT rats showed spontaneous apneic events
in a stochastic manner, whereas age matched Mecp2ZFN/y rats
tended to have multiple apneas consecutively (Fig. 8B). For
example, only 0% and 2.7% of apneas observed in juvenile and
adult WT rats occurred within 5 sec of another apnea, whereas
15% of all apneas observed in age matched Mecp2ZFN/y rats oc-
curred within 5 sec of another apnea. This tendency for con-
secutive apneas is consistent with an unstable pattern of
breathing.
Discussion
This rat study represents the first RTT developmental and
behavioural evaluation of its kind outside of traditional murine
models of the disease. Our data indicate that male RTT rats
demonstrate a complete absence of MeCP2 protein and an early
onset of rapidly progressive disease, with 50% dying by PND
55. No Mecp2ZFN/y rat in our study survived past PND 72.
Mecp2ZFN/þ rats show an approximate 50% reduction in MeCP2
protein and a more protracted, variable, and less severe disease
progression than that of affected males. Our data indicate that
Figure 6. Mecp2ZFN/y males display motor abnormalities upon CatwalkTM testing as early as PND 21. (A–B) Mecp2ZFN/y males cross the runway slower (A) and with a
greater number of steps (B) than WTs. (C)Mecp2ZFN/y males show differences in 3-paw support type at PND 21–28 and PND 50þ. (D–E) Right hind swing speed was signif-
icantly decreased in Mecp2ZFN/y males at PND 21–28, and right front and right hind swing speed (D), as well as right front and right hind stride length (E) were signifi-
cantly decreased at PND 50þ. (F) No significant differences were seen in regularity of step pattern between Mecp2ZFN/y males and WTs. (G) Representative image of
footsteps of WT (top) and Mecp2ZFN/y male (bottom) rats as they cross the CatwalkTM at PND 50þ; R/L F/H ¼ right/left front/hind, AB ¼ abdomen. (PND 21–28 WT n¼10
Mecp2ZFN/y n¼10; PND 50þ WT n¼ 12 Mecp2ZFN/y n¼14). Data are presented as mean 6 SE, with asterisks representing significant differences (*P<0.05, **P<0.01,
***P<0.001, ****P<0.0001).
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the current rat model displays a variety of phenotypic charac-
teristics reminiscent of classical RTT, which positions it as a
valuable mammalian model for future studies. A relative com-
parison of this model to other murine RTT models is provided
in Table 2.
General RTT phenotype
In females with RTT, disease overtly presents between 6–18
months of age, and symptom progression occurs over a period
of years. In XY males, however, mutations in MECP2 result in fa-
tal neonatal encephalopathy due to the x-linked nature of the
disease, or, rarely, a more classical RTT presentation (47–49).
Paralleling findings in humans, Mecp2ZFN/y rats became symp-
tomatic within weeks of birth and died early, all findings that
are corroborated by earlier reports in various mouse models
(10–12,20–22,37,50,51).
While male animal models have long provided utility in
the study of RTT due to their advanced disease time course
as well as a relative lack of phenotypic variability, the additional
Figure 7. Mecp2ZFN/þ females display motor abnormalities upon CatwalkTM testing as early as PND 21. (A–B) Mecp2ZFN/þ females cross the runway slower (A) and with a
greater number of steps (B) than WTs. (C) Mecp2ZFN/þ females show differences in 3-paw support type beginning at PND 21–28. (D) The base of support between the
hind paws is significantly increased in Mecp2ZFN/þ females beginning at 6 months of age. (E) Right hind print area is significantly decreased in Mecp2ZFN/þ females at
PND 21–28. (F–J) Regularity index (F) is not significantly altered in Mecp2ZFN/þ rats, although right front (G) and right hind (I) stride length and right front (H) and right
hind (J) swing speed were significantly decreased in these females at various points throughout development. (PND 21–28 WT n¼14 Mecp2ZFN/þ n¼10; PND 40–60 WT
n¼10 Mecp2ZFN/þ n¼10; 6 mo WT n¼11 Mecp2ZFN/þ n¼11; 9 mo WT n¼11 Mecp2ZFN/þ n¼9; 12 mo WT n¼10 Mecp2ZFN/þ n¼10; 15 mo WT n¼13 Mecp2ZFN/þ n¼13). Data
are presented as mean 6 SE, with asterisks representing significant differences (*P<0.05, **P<0.01, ***P<0.001).
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examination of female animal models is critical for both a
comprehensive understanding of disease phenotype, which
depends heavily on random X-chromosome inactivation in
female patients, and a prediction of therapeutic potential (52,53).
Similar to reports in RTT mouse models, we found that Mecp2ZFN/þ
rats became symptomatic on a more variable and lengthened
time course than males, with most displaying overt progressive
symptoms between 6 and 9 months of age.
Body weight and brain size in RTT
Females with RTT often display abnormalities in growth, in-
cluding body weight regulation, leading to the incidence of both
overweight and underweight individuals within the disease
population (54–56). Additionally, it has long been known that
RTT females display microcephaly on a gross anatomic scale,
with brain volume generally being reduced by 25% (57–59).
Mouse models of RTT have demonstrated a wide variety
of genotype-specific weight changes, with strain background
being considered a major determinant of this feature. Similar
to two previous reports (14,15), we found that body weight
was the same between Mecp2ZFN/y rats and WTs at all time
points. In contrast, we report a significant increase in
Mecp2ZFN/þbody weight beginning at 2–3 months of age and
continuing through development. Several previous mouse
studies also report weight gain in heterozygous females
(11,13,42,44).
Figure 8. Mecp2ZFN/y males display breathing abnormalities consistent with RTT. (A–B) Representative raw data plethysmography traces illustrate (A) eupnic breathing
and (B) spontaneous apneic events in WT (top tracings) and Mecp2ZFN/y (bottom tracings) juvenile males (PND 21–28). Summary data show that juvenile and adult (PND
40þ) Mecp2ZFN/y rats hypoventilate (C) but with no change in TV (F), MV (G), or respiratory irregularity (H) (PND 21–28 WT n¼8, Mecp2ZFN/y n¼11; PND 40þ WT n¼6,
Mecp2ZFN/y n¼7). Consistent with reduced respiratory frequency, juvenile Mecp2ZFN/y rats also showed an increase in Ti (D) and Te (E). Data are represented as mean 6
SEM, with asterisks representing significant differences (*P< 0.05, **P<0.01, ***P<0.001). _ designates sigh-like augmented breaths; # identifies apneic events.
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We additionally found that Mecp2ZFN/y wet brain weight was
decreased by PND 14, preceding significant findings on other
behavioural tests evaluated herein as well as previous reports
of reduced brain volume and weight in PND21þmale mice
(36,40). In affected female mice, small (4%) reductions in brain
volume have been reported as early as PND 21 by magnetic reso-
nance imaging (40), matching our report of sustained reduction
in Mecp2ZFN/þbrain weight beginning early in development. All
of our findings coincide with early abnormalities in ultrasonic
vocalization, postural reflex, and breathing patterns reported in
several mouse studies (39,60–63).
Motor dysfunction
Impairments in motor skills are prominent features in RTT,
with the majority of patients either never gaining the ability to
walk or losing this skill by adulthood (64–66). Subtle alterations
in general movements may be observable in infants within the
first several months of life (67,68), and various abnormalities in
muscle tone are often present both early and late in the disease
course (64,65,69).
We observed a decrease in overall locomotor activity as as-
sessed by the open field test in Mecp2ZFN/y rats relative to WTs
as early as PND 21. Mecp2ZFN/þ rats displayed a similar trend,
with significance being reached periodically beginning at 6
months of age. This generalized lethargy and reduction in free
ambulation has also been observed in male and female RTT
mice relatively early in development (10,22,39,70–74).
When testing paradigms that incorporated motivational
factors, such as fear of falling or an appealing dark box, were
utilized such that motor coordination per se could be more
specifically assessed, we observed that Mecp2ZFN/y and
Mecp2ZFN/þ rats performed more poorly overall than their WT
counterparts. Similar to findings in previous studies (22),
Mecp2ZFN/y rats demonstrated decreased latency to fall from a
rotating rod as early as PND 21. Mecp2ZFN/þ females demon-
strated reduced latency to fall at 9 months of age; however,
this difference did emerge after Mecp2ZFN/þ rats became heavier
than WTs, making it difficult to definitively determine a
weight-independent effect. Previous studies have reported re-
ductions in latency to fall in heterozygous females as early as
PND 30 (22), while others have indicated that motor coordina-
tion deficits emerge between 5 weeks and 12 months of age
(11,13,22,37,39,42,44,73,74).
Gait assessment revealed alterations in the manner in which
Mecp2ZFN/y and Mecp2ZFN/þ rats crossed a glass walkway; namely,
Figure 9. Aged Mecp2ZFN/þ females display breathing abnormalities. Adult (18 month) Mecp2ZFN/þ females hyperventilate (A), with corresponding decreases in Te (B) rela-
tive to WT females (PND 18 mo WT n¼5 Mecp2ZFN/þ n¼5). (C–H) TI (C), TV (D), MV (E), irregularity score (F), apnea occurrence (G), and apnea duration (H) did not signifi-
cantly differ between Mecp2ZFN/þ females and WTs. Data are represented as mean6 SEM, with asterisks representing significant differences (**P<0.01).
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they crossed more slowly, took a greater number of steps, and
utilized different types of body support mechanisms to accom-
plish this goal. Trends toward altered features in Mecp2ZFN/þ fe-
males generally reached significance at only some time points,
which was not altogether surprising given the wide phenotypic
variability commonly seen in female mouse models of RTT as
well as female patients. Previous reports have demonstrated
findings of decreased stride length and increased step fre-
quency in male RTT mice as early as 3–4 weeks of age (37,51,71),
and gait ataxia as early as 1–4 months of age in heterozygous fe-
male mice (10,11). Interestingly, while the hindpaw width of
stance was increased in Mecp2ZFN/þ rats, a finding that has been
previously reported in mice (51,71), forepaw width of stance and
paw print areas were not correspondingly increased as may
have been predicted from significant average body weight
increases in Mecp2ZFN/þ rats relative to WTs. The persistence
of gait regularity (observed also in (71)) in the presence of these
support type variations in both Mecp2ZFN/y and Mecp2ZFN/þ rats
seems to indicate that profoundly symptomatic animals are ca-
pable of compensating to accomplish motivated ambulation.
Other physical and behavioural manifestations of
disease
Malocclusion
The majority of Mecp2ZFN/y rats (80%), but only 5 Mecp2ZFN/þ
females, demonstrated severe uneven tooth wear necessitating
euthanasia during our study. Dental malocclusion has been ob-
served in other RTT models (10,12). We assume that the low in-
cidence of this feature in female rats was due to their
possession of one functional Mecp2 copy; however, malocclu-
sion was previously reported as a “common” occurrence in fe-
male mice (12). Rodents’ teeth grow continuously and require
constant gnawing to maintain normal wear. Malocclusion may
have indirectly resulted from a change in the animals’ ability or
desire to feed due to global MeCP2 absence, a feature that might
parallel the gastrointestinal autonomic dysfunction and feeding
difficulties observed in girls and boys with RTT (48,75,76).
Alternatively, malocclusion may directly result from MeCP2 ab-
sence in the peripheral tissues related to tooth development
and growth; however, given that decelerated weight gain
seemed to precede tooth lengthening and the time course of
this feature’s development varied significantly, it seems as
though the former may be the more probable explanation.
Regardless, the development of malocclusion will be critical to
consider in any future study utilizing affected male rats.
Stringent evaluation of weight gain/loss will be necessary to
track potential nutritional deficits, and stratification of affected
males into groups based on the development of malocclusion
may yield interesting phenotypic findings.
Hind limb clasping
The development of hand stereotypies is a key diagnostic fea-
ture of classic RTT (5–8,77). The presence of hindlimb clasping
upon tail suspension in animal models of RTT has been sug-
gested to recapitulate this principle finding, although this fea-
ture is observed in many rodent models of neurologic disease
(78–81). In this study, the majority of Mecp2ZFN/y and Mecp2ZFN/þ
rats displayed hindlimb clasping at some point during develop-
ment, as has been previously reported in many mouse models
of RTT.
Breathing irregularities
RTT patients often develop irregular breathing characterized by
periods of hyperventilation interspersed with apnea or breath
holds (82). Mouse models of RTT typically report normal respira-
tory activity under control conditions (inactive, breathing room
air) up to PND 20 (63,83) followed shortly thereafter by abnor-
malities in post-sigh breathing (63), and later hyper- (84,85) or
hypo-ventilation (62,83,86,87) with increased tidal volume
(86,88) in conjunction with increased apneic frequency and du-
ration (89–91). These respiratory abnormalities are partly reca-
pitulated in juvenile and adult Mecp2ZFN/y rats, which
demonstrate decreased respiratory frequency, as well as
Mecp2ZFN/þrats, which show increased frequency. However, our
evidence suggests that there are species-specific effects of
MeCP2 deficiency on respiratory function. While reoccurring ap-
neas are a characteristic breathing feature in RTT patients
(82,90,91) and several mouse models of RTT (90,91), our data
show that disruption of MeCP2 in rats does not lead to an
overtly apneic phenotype. Furthermore, breathing irregularities
in RTT mice typically develop after PND 30 and progressively
worsen with age (62,63,83). Our data in MeCP2 deficient rats sug-
gest that respiratory problems are not progressive, and indeed
in humans, breathing problems may actually be more severe at
younger ages (92). Together, these findings suggest that our un-
derstanding of respiratory dysfunction associated with RTT is
far from complete, and underscore the need for further exami-
nation of animal models of this disease.
Seizures
EEG abnormalities and seizures are frequently observed in RTT
patients, with seizure prevalence being approximately 60% (93–
98). In Mecp2ZFN/y males, we observed seizures as early as the
fourth postnatal week, and most strikingly in symptomatic
older Mecp2ZFN/þ females upon behavioural testing or handling.
Previous RTT mouse studies have reported seizures as early as
the 5th–7th postnatal week in males (11,13,37,99–101) and 4
months of age in females (22). Although the absence of 24-h
video or EEG monitoring made it difficult to define these epi-
sodes as seizures and quantify their prevalence, the abnormal
behaviour and posture of the rats during these events were
clearly reminiscent of seizure activity. The future quantification
of seizure activity in this model is warranted, and studies in the
rat would be particularly appealing due to the animals’ large
size and the advantages that this would confer in electrode im-
plantation and EEG recording.
Social aggression
While we did not pursue additional testing measures of social
interaction in this model, we did observe many instances of
Mecp2ZFN/y-initiated aggression that resulted in the severe
wounding of littermates. These findings may be related to previ-
ous reports of altered aggressive or defensive behaviours
(17,18,99,102) and anxiety-like behaviours (19,20,22,37,38,
44,50,61) in RTT mouse models as well as in patients (reviewed
in (53)). This aggressive behaviour was not observed in
Mecp2ZFN/þ females.
Musculoskeletal features
Abnormal curvature of the spine, while prevalent in RTT pa-
tients (103) and reported in previous mouse models (14), was
not observed in any rats in our study. Throughout development,
however, Mecp2ZFN/y and symptomatic Mecp2ZFN/þrats were gen-
erally much more easily handled and examined than their WT
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counterparts due to the display of significant hypotonia. This
observation has not previously been described in mouse models
of RTT (25), although early hypotonia is well described in hu-
man patients with MECP2 mutations (65,67,104), and several
mouse studies have reported alterations in muscular strength
in males and females (14,22,37,38,70). A recent study utilizing a
conditional MeCP2 knockout model has demonstrated that loss
of MeCP2 affects skeletal muscle through a non-cell autono-
mous mechanism leading to disorganized hypotrophic fibres
and fibrosis (105). Preliminary results not presented herein sug-
gest that muscular strength, as assessed by the wire hang and
grip strength tests, may be reduced in both juvenile Mecp2ZFN/y
males and 12 month Mecp2ZFN/þ females; however, genotype-
specific body weight differences made these results difficult to
meaningfully interpret given that the testing paradigms and
data analysis rely heavily on body weight. It is clear that muscle
tone is significantly altered, whether mediated through a cen-
tral or peripheral mechanism, in this rat model. The current
model offers a clear advantage in that the sheer size of the labo-
ratory rat makes such features easily detectable.
Concluding Remarks
The characteristics observed in Mecp2ZFN/y and Mecp2ZFN/þ rats
demonstrate many parallels to those displayed by various
mouse models as well as in patients with RTT. It is worth noting
that the authors of this publication have additional experience
working with the Jaenisch null mouse model of RTT (11), and
many of the symptoms described herein are more readily ap-
parent and pronounced in the rat than in the smaller laboratory
mouse, especially at very early developmental stages. We be-
lieve that this study opens the door to a new avenue of research
in the RTT field, as it not only characterizes an entirely new spe-
cies model of this genetic condition, but does so in both male
and female MeCP2-deficient rats throughout development. This
novel rat model may serve as a critical tool in improving our un-
derstanding of disease progression and subsequently aiding in
the development of stage-specific therapeutics.
Materials and Methods
Subjects
All experimental protocols were in accordance with the NIH
guidelines and were carried out with approval from the Animal
Care and Use Committee of the University of Alabama at
Birmingham (Animal Permit Number: 09409). Every effort was
made to minimize pain and discomfort. Animals used in all ex-
periments were littermates bred in our animal facility by
crosses of Mecp2ZFN/þ females (SD- Mecp2tm1sage) to wildtype
(WT) S100b eGFP (enhanced green fluorescent protein) males
obtained from the National Bioresource Project Rat (Japan) (106).
This breeding regimen was maintained due to our inherent in-
terest in the study of the role of astrocytes in the pathophysiol-
ogy of RTT. All rats were genotyped by PCR using DNA obtained
from tail snips and Clontech’s Terra PCR Direct Genotyping kit.
Primers used were the following: forward 5-GCAGCATCA
GAAGGTGTTCA-3 and reverse 5-GACCTCAATGCTGACGGTTT-3.
Expected bands were the following: WT¼ 345bp, Mecp2ZFN/y
¼ 274bp, and Mecp2ZFN/þ¼ 345 bp and 274bp (see Fig. 1A).
Subjects were sacrificed during the study if they displayed ac-
tive malocclusion, deteriorating body condition, or if they were
required for brain weight evaluation. Time between behavioural
evaluations in repeatedly tested animals was always at least
two weeks. Studies in male rats were not pursued after active
malocclusion presented. Animals were housed under standard
conditions of 12-h light-dark cycles and were provided with wa-
ter and food available ad libitum.
Western blotting
Brain regions were dissected from whole tissue and sonicated
in lysis buffer containing 1M Tris pH 7.5, 10% SDS, and 1:10 pro-
tease and phosphatase inhibitors. Equal amounts of protein
(10mg and 7mg of protein from male and female animals, respec-
tively) were electrophoresed on 4–20% Mini-PROTEAN TGX pre-
cast polyacrylamide gel (BioRad) for 1.5 h at 200V at room
temperature and transferred onto methanol-activated PVDF
membranes (Millipore) at 100V for 1 h stirring with a cold pack.
Membranes were blocked in 10% nonfat milk prepared in TBS-T
shaking for 1 h at room temperature, incubated shaking with
mouse monoclonal antibodies against the C-terminus of MeCP2
at 1mg/mL (Sigma) in blocking buffer for 2 h at room temperature
(female rat cortex) or 4 h at room temperature (male rat cortex
and brainstem), washed 35 min in TBS-T, and incubated shak-
ing with anti-mouse HRP-conjugated IgG 1:2000 (Santa Cruz
Biotechnology, lot #E3113) for 1 h at room temperature.
Following 35 min washing with TBS-T, blots were developed
using Millipore Luminata Classico Western HRP substrate. Clear
MeCP2 bands were observed at the expected molecular weight
of 75 kD; however, non-specific bands were observed at 200, 50
and 40KD, and were present in WT, Mecp2ZFN/y and Mecp2ZFN/þ
lanes. For clarity, only the immunoreactive bands at the ex-
pected molecular weight for MeCP2 are shown. Blots were then
washed 30 min in TBS-T and incubated shaking with chicken
polyclonal antibodies against GAPDH 1:2000 (Millipore) in block-
ing buffer for 35 min, washed 35 min in TBS-T, incubated shak-
ing with anti-chicken HRP-conjugated IgY 1:2000 (Santa Cruz
Biotechnology, lot #I2612) for 35 min and developed as above.
MeCP2 bands were quantified using Licor ImageStudio Version
4.0, normalized to GAPDH, and averaged based on genotype.
Brain and body growth curves
Animals were weighed on a weekly basis to the 1/10th gram to
evaluate overall growth and monitor for any weight loss that
might necessitate sacrifice. For ages at which brain weights
were evaluated, animals were anaesthetized with CO2 and de-
capitated. Brains were removed from the skull and weighed to
the nearest 1/10th gram. For body weight evaluation in males,
only those rats that did not go on to develop malocclusion by
PND 50 were included in analysis, as decelerated weight gain
seemed to precede severe tooth lengthening, and active maloc-
clusion led to weight loss. Brain and body weights for each time
point evaluated were averaged based on genotype.
Generation of symptom scores
Symptom scores (0–9) were generated on a weekly basis during
an observation time of approximately 3–6 min per cage based
on the summation of the scores from eight characteristics, with
a total score of 9 representing a maximally symptomatic ani-
mal. General activity level was scored from 0 to 2, with normal
activity (0) including cage exploration, interaction with cage-
mates, and rearing on the hindquarters during experimenter re-
moval of cage lid, and abnormal activity ranging from lethargic
cage exploration and no hindlimb rearing (1) to extreme
3315Human Molecular Genetics, 2016, Vol. 25, No. 15 |
lethargy or a complete lack of movement during the observation
period (2). The presence of hindlimb clasping, breathing abnor-
malities (gasping, “hiccuping” or breath holding), waddling or
low-clearance gait, unkempt fur, fur loss, urine staining around
the genitals, and porphyrin around the eyes or nose all individ-
ually yielded a score of 1. Symptom scores were averaged based
on genotype and reported for each age.
Open field test
One session consisted of placing each rat in the centre of an
open field arena (70  70cm) surrounded by clear plastic walls
and recording for a 4-min period. All movement was captured
using a camera mounted above the arena and was quantified by
Ethovision XT version 11 software (Noldus). Single-session ge-
notypic values were averaged at each time point reported.
Rotor rod test
During one testing session, rats were placed on an accelerating
rod of a 5.75” diameter (San Diego Instruments) for three train-
ing trials with 2 min rest between each, followed by three re-
corded test trials with 2 min rest between each. Each trial lasted
for a maximum of 10 min, with the rod accelerating linearly
from 0 to 5 rpm for the first 30 s, 5 to 10 rpm, 10 to 15 rpm, and 15
to 20 rpm for the remaining three 1.5 min segments, and staying
at 20 rpm for a maximum of 5 min if any animal remained on
the rod. The amount of time for each rat to fall from the rotating
rod onto a foam pad 48” below was recorded for each test trial.
Latency to fall values from the three test trials were averaged
for each animal and within-genotype session averages were cal-
culated at each age reported.
Catwalk test
All rats were trained with 3 trials on the Catwalk device
(Noldus) one week prior to their first testing session. In short,
rats were placed at one end of a glass plate of width 10 cm
(adults) or 6 cm (pups) enclosed by two opaque walls and a ceil-
ing, and moved toward the other end, which provided an
enclosed dark box as a motivating factor for advancement along
the surface. During the testing session, trials were video re-
corded by a camera placed 48.5 cm below the plexiglass surface,
thereby capturing the ventral surface of the animals and allow-
ing for measurement of paw placement. For each animal, the
first three trials meeting a requirement of<100% within-trial
speed variation were kept for analysis. Noldus Catwalk XT ver-
sion 10.5 software was used to evaluate all gait parameters re-
ported in this study. The Noldus formula used to calculate the
regularity index for each trial is as follows: [(NSSP  4)/PP] 
100%, where NSSP represents the number of normal step se-
quence patterns and PP the total number of paw placements
within the trial. The support type values reported reflect the
percentage of time in each trial during which the animal had
three paws simultaneously placed on the plexiglass plate. For
each animal, the value of each reported parameter was deter-
mined as an average of the three recorded session test trials,
and these values were averaged based on genotype at each age
shown.
Whole-body unrestrained plethysmography
Respiratory activity was measured using a constant flow whole-
body plethysmograph system (Buxco), utilizing animal cham-
bers (PLY3211 and PLY3213) maintained at room temperature
and ventilated with air (1000 mL/min). Respiratory-induced
changes in chamber pressure were detected using a pressure
transducer calibrated before each experiment by the injection
of 1mL or 5mL of air (for PLY3211 and PLY3213, respectively)
through a Luer-lock syringe according to Buxco manual guide-
lines. During a testing session (one per animal per age reported),
animals were individually placed into a chamber and allowed
30 min to acclimate prior to data recording. Respiratory activity
was then recorded for a period of 25 min, and all experiments
were performed between 11am and 6pm to minimize potential
circadian effects. Tidal volume (TV) (measured in mL, normal-
ized to body weight and corrected to account for chamber and
animal temperature, humidity, and atmospheric pressure),
minute ventilation (MV) (mL/min/kg), inspiratory time (Ti) and
expiratory time (Te) were recorded continuously using the
BioSystem XA for Windows software with a logging rate of 5 s. A
1-min period of relative quiescence was selected from continu-
ous data traces for off-line analysis of all respiratory parameters
except apneas. Respiratory frequency (breaths per minute; BPM)
was analyzed separately using template search event detection
in Axon Clampfit 10.2 (Molecular Devices). We confirmed that
the 1-min section of data selected for analysis was devoid of
any behaviour artefacts, representative of eupneic breathing
over the 25 min period, and appeared stable (i.e., limited inter-
breath variability) as determined by plotting each breath (nþ 1)
against the previous breath (n) and constructing a Poincare plot
to confirm close clustering of data points in a manner similar to
(107).
To estimate respiratory cycle variability we calculated the ir-
regularity score (IS) as previously described (108) IS¼ 100 
ABS(Pn–Pn1)/Pn1, where IS is the irregularity score for the nth
cycle, Pn is its period, Pn1 is the period of the preceding cycle,
and ABS is the absolute value. The frequency and duration of
apneic events were determined for the entire 25-min recording.
Apneic events were conservatively defined as periods with a
Te 3 breath cycles for a juvenile WT (1.4 s) or 3 breathe cycles
for an adult male WT (1.6 s).
Statistics
Data are reported as mean6 standard error of the mean.
Statistical analysis was performed using GraphPad InStat 3
software. All parameters in this study were analyzed via
within-genotype values at each developmental time point.
Between-genotype comparisons were made independently at
each age via non-parametric (Mann-Whitney) tests.
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